GT201400034A - Compuestos y composiciones como inhibidores de la quinasa c-kit - Google Patents

Compuestos y composiciones como inhibidores de la quinasa c-kit

Info

Publication number
GT201400034A
GT201400034A GT201400034A GT201400034A GT201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A GT 201400034 A GT201400034 A GT 201400034A
Authority
GT
Guatemala
Prior art keywords
compounds
kit
quinase
inhibitors
compositions
Prior art date
Application number
GT201400034A
Other languages
English (en)
Spanish (es)
Inventor
Molteni Valentina
Petrassi Hank Michael James
Li Xiaolin
Liu Xiaodong
Loren Jon
Nabakka Juliet
Nguyen Bao
Yeh Vince
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201400034A publication Critical patent/GT201400034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
GT201400034A 2011-09-01 2014-02-27 Compuestos y composiciones como inhibidores de la quinasa c-kit GT201400034A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
GT201400034A true GT201400034A (es) 2015-02-19

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400034A GT201400034A (es) 2011-09-01 2014-02-27 Compuestos y composiciones como inhibidores de la quinasa c-kit

Country Status (30)

Country Link
US (3) US8569283B2 (OSRAM)
EP (1) EP2751104B1 (OSRAM)
JP (1) JP6134319B2 (OSRAM)
KR (1) KR101962495B1 (OSRAM)
CN (1) CN103797011B (OSRAM)
AP (1) AP2014007493A0 (OSRAM)
AR (1) AR087753A1 (OSRAM)
AU (1) AU2012302042B2 (OSRAM)
BR (1) BR112014004560A2 (OSRAM)
CA (1) CA2845169C (OSRAM)
CL (1) CL2014000492A1 (OSRAM)
CO (1) CO6900141A2 (OSRAM)
CR (1) CR20140107A (OSRAM)
CU (1) CU20140024A7 (OSRAM)
EA (1) EA026152B1 (OSRAM)
ES (1) ES2761332T3 (OSRAM)
GT (1) GT201400034A (OSRAM)
IL (1) IL231227A0 (OSRAM)
MA (1) MA35460B1 (OSRAM)
MX (1) MX339937B (OSRAM)
PE (1) PE20140909A1 (OSRAM)
PH (1) PH12014500372A1 (OSRAM)
PL (1) PL2751104T3 (OSRAM)
PT (1) PT2751104T (OSRAM)
SG (1) SG2014014369A (OSRAM)
TN (1) TN2014000068A1 (OSRAM)
TW (1) TW201313717A (OSRAM)
UY (1) UY34301A (OSRAM)
WO (1) WO2013033167A1 (OSRAM)
ZA (1) ZA201401175B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134319B2 (ja) 2011-09-01 2017-05-24 ノバルティス アーゲー ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
DK3007689T3 (en) 2013-01-10 2018-06-14 Pulmokine Inc NON-SELECTIVE KINASE INHIBITORS
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6483714B2 (ja) 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
MA42293A (fr) 2015-07-02 2018-05-09 Janssen Sciences Ireland Uc Composés antibactériens
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
US20190256509A1 (en) * 2016-06-08 2019-08-22 Chrysalis, Inc. Histone demethylase inhibitors
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
CN110831630A (zh) 2017-03-01 2020-02-21 爱尔兰詹森科学公司 组合疗法
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
MX2021013814A (es) * 2019-05-13 2022-02-10 Novartis Ag Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
EP4028399B1 (en) 2019-09-13 2024-02-14 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022016021A1 (en) 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
JP2023551434A (ja) 2020-11-19 2023-12-08 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法
MX2023010947A (es) 2021-03-16 2023-11-29 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
KR20230158046A (ko) 2021-03-17 2023-11-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
US20240182495A1 (en) 2021-03-17 2024-06-06 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CN120677154A (zh) * 2022-11-30 2025-09-19 缆图药品公司 用于治疗荨麻疹的作为野生型c-kit激酶抑制剂的n-苯基-吡唑并[1,5-a]吡啶-3-甲酰胺衍生物
JP2025541191A (ja) * 2022-12-07 2025-12-18 サード ハーモニック バイオ， インコーポレイテッド Ｃ－ｋｉｔキナーゼ阻害剤としての化合物及び組成物
KR20250129682A (ko) * 2022-12-07 2025-08-29 써드 하모닉 바이오, 인크. C-kit 키나제 억제제로서의 화합물 및 조성물
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
BRPI0515081B8 (pt) 2004-09-09 2021-05-25 Natco Pharma Ltd composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida
EP2942349A1 (en) 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Enzyme modulators and treatments
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CA2668190A1 (en) * 2006-11-03 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
AR083855A1 (es) * 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
BR112014003963A2 (pt) 2011-09-01 2017-03-21 Irm Llc compostos e composições como inibidores de quinase c-kit
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
CN104039783A (zh) 2011-09-01 2014-09-10 Irm责任有限公司 作为pdgfr激酶抑制剂的化合物和组合物
JP6134319B2 (ja) 2011-09-01 2017-05-24 ノバルティス アーゲー ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物

Also Published As

Publication number Publication date
PH12014500372A1 (en) 2014-04-07
CA2845169A1 (en) 2013-03-07
JP6134319B2 (ja) 2017-05-24
US20130059832A1 (en) 2013-03-07
CL2014000492A1 (es) 2014-10-03
MX2014002484A (es) 2014-11-25
UY34301A (es) 2013-04-05
MA35460B1 (fr) 2014-09-01
CA2845169C (en) 2022-04-19
AU2012302042B2 (en) 2016-03-31
TW201313717A (zh) 2013-04-01
CU20140024A7 (es) 2014-04-24
EA026152B1 (ru) 2017-03-31
US8569283B2 (en) 2013-10-29
AU2012302042A1 (en) 2014-04-17
EA201490545A1 (ru) 2014-07-30
US20140031333A1 (en) 2014-01-30
SG2014014369A (en) 2014-09-26
EP2751104A1 (en) 2014-07-09
CO6900141A2 (es) 2014-03-20
US8754071B2 (en) 2014-06-17
TN2014000068A1 (en) 2015-07-01
PE20140909A1 (es) 2014-07-20
KR20140075692A (ko) 2014-06-19
KR101962495B1 (ko) 2019-03-26
CR20140107A (es) 2014-05-02
WO2013033167A1 (en) 2013-03-07
CN103797011B (zh) 2016-03-30
EP2751104B1 (en) 2019-09-25
MX339937B (es) 2016-06-17
AP2014007493A0 (en) 2014-03-31
ES2761332T3 (es) 2020-05-19
BR112014004560A2 (pt) 2017-04-04
US20140228347A1 (en) 2014-08-14
CN103797011A (zh) 2014-05-14
US9023839B2 (en) 2015-05-05
AR087753A1 (es) 2014-04-16
ZA201401175B (en) 2015-01-28
PL2751104T3 (pl) 2020-04-30
PT2751104T (pt) 2019-12-16
IL231227A0 (en) 2014-04-30
JP2014525448A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
ECSP23004573A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CU20140139A7 (es) Compuestos y composiciones para modular la actividad de egfr
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX382607B (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa.
DOP2014000233A (es) Compuestos de microarn y métodos de modulación de la actividad de mir-21
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CR20170478A (es) Compuestos novedosos
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
MX379814B (es) Proceso para preparar compuestos de dihidroisoquinolinas-fenil-purinas.
EA201490542A1 (ru) Соединения и композиции в качестве pdgfr киназных ингибиторов
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
MX2019001011A (es) Compuestos farmaceuticos.
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
BR112015000051A2 (pt) tratamento de distúrbios inflamatórios da pele
MX2015003701A (es) Composiciones para tratamiento.
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina
CR20140289A (es) Derivados de quinolina como inhibidores de la enzima pde10a